Zacks Small-Cap Research

November 10, 2015

Lisa Thompson
312-265-9154
lthompson@zacks.com

scr.zacks.com

10 S. Riverside Plaza, Chicago, IL 60606

Finjan Holdings (FNJN-NASDAQ)

FNJN: 10Q Hints at New Deals Coming Soon

UPDATE

Finjan, is positioned to grow not only by pursuing IP licensing, but also by cybersecurity consulting and investment new IP via R&D. Its August win against Blue Coat should spur new licensing deals and reap considerable cash rewards in 2017. The delays in the Symantec and Proofpoint cases, as well as no news of new licensing deals since August, have hurt the stock. This lull in activity should be considered a buying opportunity for investors as the 10Q hints at new deals coming soon.

Current Recommendation	**Buy**
Prior Recommendation	Buy
Date of Last Change	9/15/2014
Current Price (11/09/15)	$1.35
Target Price	**$3.75**

SUMMARY DATA

52-Week High	**$3.13**
52-Week Low	**$1.23**
One-Year Return (%)	**-54.7**
Beta	**-0.84**
Average Daily Volume (sh)	**452,172**
Shares Outstanding (mil)	**23**
Market Capitalization ($mil)	**$30**
Short Interest Ratio (days)	**1.90**
Institutional Ownership (%)	**27**
Insider Ownership (%)	**30**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/M**
Earnings Per Share (%)	**N/M**
Dividend (%)	**N/M**
P/E using TTM EPS	**N/M**
P/E using 2015 Estimate	**N/M**
P/E using 2016 Estimate	**2.7**
Zacks Rank	**N/A**

Risk Level	**High**
Type of Stock	**Small-Blend**
Industry	**Internet-Software**

ZACKS ESTIMATES

Revenue
(in millions of $- Restated)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2013	0.0 R	0.0 R	0.0 R	0.0 R	0.0 R
2014	0.0 R	0.0 R	5.0 R	0.0 A	5.0 A
2015	0.0 A	0.7 A	0.0 A	0.3 E	1.0 E
2016	4.6 E	2.7 E	2.8 E	3.0 E	13.0 E

Earnings per Share
(Restated EPS is continuing operating earnings before non-recurring items)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2013	NA	NA	NA	NA	-$0.26 A
2014	-$0.08 R	-$0.15 R	$0.03 R	-$0.18 A	-$0.38 A
2015	-$0.19 A	-$0.12 A	-$0.21 A	-$0.18 E	-$0.74 E
2016	-$0.01 E	-$0.11 E	-$0.10 E	-$0.09 E	-$0.37 E

© Copyright 2015, Zacks Investment Research. All Rights Reserved.

10Q Alludes to New License Deals

After Finjan's win against Blue Coat, we had hoped that licensing deals would accelerate, but Q3 has come and gone without a new one. Additionally, Finjan v. Palo Alto Networks (PANW) has been reassigned and all pending dates will be reset in accordance with the new judges calendar. In Finjan v. Symantec (SYMC), the judge has stayed the case pending a decision by the US Patent and Trademark Office (USPTO) on whether to institute Inter Partes Review (IPR) of Finjan's patent claims in five of eight patents asserted against Symantec. Depending on the PTAB's decision on whether or not to institute those IPRs, the judge will determine whether to extend the stay. This pushes out the calendar on the largest possible win due to the size of Symantec's revenues in cybersecurity.

However the 10Q, by maintaining the company has enough cash to fund operations for the next 12 months, hints that new deals will soon be reached given its plans and current cash burn do not support that time period.

Q3 2015 Results

The company burned $4.5 million in cash in Q3 2015 versus $3.8 million in the June quarter. By January 15, 2016 it will receive another $2 million, and another $300,000 by March 30, 2016 from previously scheduled payments. With $7.2 million in cash as of September 30, it has just over 6 months of cash at that burn rate, although in the 10Q the company states it believes it has 12 months reserve based on what it knows. This leads us to conclude that they have a very high likelihood of new licensing deals or settlements in the next few months or they would not have put that language in the 10Q. (For now we are keeping revenues only from the consulting business in our estimate.)

Finjan reported no revenues in Q3. Operating costs for the quarter were broken down for the first time between SG&A and R&D and the two together were $4.7 million versus $3.5 million last year and up $137,000 since the June quarter of 2015 rather than down as we had expected with the Blue Coat trial over. The company ended up spending more on expert witnesses and on introducing evidence that it had expected, but costs should decline in Q4.

Q4 and 2015 Annual Forecasts

Although impossible to forecast, we are assuming no additional licensing deals this year. For now we are keeping revenues only from the consulting business in our estimate. We expect that new business to show its first revenues shortly. With minimal revenue expected and only a slight reduction in SG&A for Q4 we are forecasting a loss of $0.18 per share for the quarter, or $4 million. This will result in a loss of $0.74 per share for the year on revenues of $1 million.

2016 Forecast

We are lowering our 2016 revenue forecast to reflect a shift of the revenues from the Blue Coat win to mid-2017. We are assuming over the course of the year other companies will license resulting in total revenues of $13 million. This comprised of $9 million in new licenses, the $2 million owed by Websense to be paid in Q1 and $2 million projected for the new cybersecurity consulting business.

We anticipate slightly higher spending on SG&A, half of which will be to support the Proofpoint and Sophos trials. With these revenues and expenses we expect a reported loss per share of $0.37 per share or $8.3 million.

Blue Coat Should Be Recognized in 2017

By mid-2017, the appeal in the Blue Coat trial should be settled and if the appeal is denied Finjan will collect $39.5 million for the judgment and 10% interest per year since August 5, 2015 on the $39.5 million which may be $900,000 or so. In addition, more money will accrue from the products that Blue Coat has sold since August 5, 2015.The biggest cost difference for the company will be for taxes paid on this judgment. We believe the company has at least $2 million tax loss carry forward to be subtracted off the 35% US and 8.86% California tax rates.

NEXT EVENTS

We are still waiting for the results of the Markman hearing with Proofpoint that took place on June 24, 2015. The judge as explained above has stayed the results from the Markman hearing with Symantec that occurred on June 29, 2015. The Proofpoint trial is scheduled to start March 7, 2016.

The Win Against Blue Coat

The big win for Finjan against Blue Coat on August 5, 2015, has increased the value of Finjan significantly as more of its patents have proven to have value and it has more ammunition with which to convince other entities to license its technology. While all six patents were considered valid, the jury decided one, 822, was not applicable to Blue Coat's products. The award breakdown according to papers filed by the jury was as follows, with 844 being the big contributor.

Patent Number	*$ In Millions*	*Filed*
6,154,844	24.00	1997
7,058,822	0	2001
7,647,633	1.67	2005
7,418,731	6.00	2004
6,965,968	7.75	2003
6,804,780	0.11	2000

At any rate litigation with Blue Coat has not ended. Most likely should Blue Coat not settle, it will appeal, a process that could take another 12-18 months. We have tentative put revenue from this judgment in 2017. In addition there is the new suit against it that encompasses seven patents and addresses new products that have been introduced by Blue Coat since the lawsuit just won was filed in 2013. Specifically the company named certain of Blue Coat's ProxySG Appliances and Software, the ProxyAV Appliances and Software, and WebPulse Services (some of which Blue Coat recently launched) as products that are infringing.

The patents Finjan believes are being infringed upon in this new suit are: 6,154,844; 6,965,968; 7,418,731; 8,079,086; 8,225,408; 8,566,580 and 8,677,494, the last four of which are being asserted against Blue Coat for the first time. According to its press release "Finjan is seeking a jury trial; entry of judgment of direct and indirect infringement of certain claims of each of the asserted patents by Blue Coat; preliminary and permanent injunction against Blue Coat and its officers, among others, from infringing the asserted patents; and damages to be determined by a jury."

KEY POINTS

- Finjan holds a number of pioneering patents for cybersecurity hardware and software that is relevant to dozens of companies in this space.
- The company's non-compete with Trustwave has ended and they are pursuing new product launches.
- While its patents have already generated > $150M in its licensing and enforcement track record, the company has the potential to continue to reap large licensing revenues from the $20 billion market for cybersecurity software, services and appliance market.
- The technology licensing market in the U.S., once an afterthought, has grown from $33 billion in 1994 to $68 billion in 2002 and is likely over $100 billion today.
- The company's win against Blue Coat proves its patents are still valued and able to be successfully defended and therefore monetized.
- The company's has a market cap of $30 million and approximately $7 million in cash but could be worth considerably more if it is successful in its licensing pursuits. Estimating revenues of $13 million in 2016 and $53 million in 2017 and an industry multiple of 3.4 times sales, the company could be worth as much as $189 million by 2017 if it succeeds in reaching new licensing arrangements.

OVERVIEW

Finjan Holdings is a patent licensing and enforcement firm based in NYC that owns the patents of its predecessor company Finjan Inc., a cybersecurity company that was founded in Israel in 1997. It invented several technologies that are used in current cybersecurity products today. Its three main patent areas:

- Behavior-based methods to detect and prevent threats from the Internet, including email and Web malware
- "Sandboxing" or stripping applications and running potentially malicious code in a safe environment
- Mobile code replacement where the malicious code is stripped and replaced by safe code

CYBERSECURITY MARKET

The market for cyber security products that may use technology covered by Finjan patents is expected to total $20 billion in sales in 2014, according to estimates by Gartner. These types of products include: endpoint and cloud, web gateway and next generation firewall software and hardware products as shown on the following chart.

Relevant Security Markets	2013	2014	2015	2016	2017
Endpoint & Cloud	$11.2 BN	$11.8 BN	$12.5 BN	$13.2 BN	$13.8 BN
Web Gateway	$4.1 BN	$4.4 BN	$4.7 BN	$5.0 BN	$5.3 BN
Next Gen. Firewall	$4.0 BN	$4.0 BN	$4.0 BN	$3.7 BN	$3.4 BN
Total Finjan Technology related Sales	$19.3 BN	$20.2 BN	$21.2 BN	$21.9 BN	$22.5 BN

Source: Gartner, IDC and Finjan estimates

Cybersecurity Consulting Business

According to Gartner, the market for information security consulting grew by 8.1% to $15.3 billion in 2014, from $14.2 billion in 2013. Combined, the top 10 providers grew by 12.7%. Three quarters of revenue comes from North America and Western Europe. Deloitte was ranked number one in this market. Other players, and competitors for Finjan in the cybersecurity consulting business include FireEye's Mandiant division, Hacknetics, a division of Ernst & Young, and root9B (RTNB) as well as IBM and Symantec.

Litigation Update

Company	Date and Location	Status	Patent numbers
FireEye **($426 m)**	US District Court for the Northern District of California on July 8, 2013	Stayed	**6,804,780**, 8,079,086, 7,975,305, 8,225,408, **7,058,822**, 7,647,633 and 6,154,844
Blue Coat **(est. >$500m)**	US District Court for the Northern District of California on August 28, 2013 US District Court for the Northern District of California on July 16, 2015	**Won $40m judgment. All patents upheld. Only 7,058,822 did not infringe.** Just filed	6,154,844, **6,804,780**, 6,965,968, **7,058,822**, 7,418,731, and 7,647,633 6,154,844; 6,965,968; 7,418,731; 8,079,086; 8,225,408; 8,566,580; 8,677,494
Proofpoint **($196 m)**	United States District Court for the Northern District of California on December 16, 2013	"Markman" occurred **June 24, 2015**. Awaiting results. Trial date for March 7, 2016.	6,154,844, **7,058,822**, 7,613,918, 7,647,633, 7,975,305, 8,079,086, 8,141,154, and 8,225,408
Sophos **(est. $420 m)**	United States District Court for the Northern District of California on March 14, 2014	Markman concluded. Trial date September 16, 2016.	6,154,844, **6,804,780**, 7,613,918, 7,613,926, 7,757,289, 8,141,154, 8,566,580, and 8,677,494
Symantec **($6.6 billion)**	United States District Court for the Northern District of California on June 1, 2014	"Markman" occurred **June 29, 2015**. Awaiting results. Stayed pending decision by USPTO.	6,154,844; 7,613,926; 7,756,996; 7,757,289; 7,930,299; 8,015,182; 8,141,154; and 8,677,494
Palo Alto Networks ($739 m)	United States District Court for the Northern District of California on November 4, 2014	Reassigned to another judge. "Markman" will be rescheduled.	**6,804,780**; 6,965,968; **7,058,822**; 7,418,731; 7,613,918; 7,613,926; 7,647,633; 8,141,154; 8,225,408; and 8,677,494

Highlighted patent numbers have been successfully defended in court.

VALUATION

Valuation of an IP company, even with a track record is very difficult and even more so with a company like Finjan that has only one court victory and one recent licensing arrangement. We can however look at other IP companies to see how the market values them to make some comparisons. There seems to be two different types of companies in this space, the older stable revenue generating companies like Rambus, and the upstarts that trade on events and potential. We can see from the table below, these range from Unwired Planet with a $7 million enterprise value, to Interdigital with an enterprise value of $1.6 billion and $401 million in sales expected this year. On average, the companies with revenues trade at an average of 3.5X 2015 estimated calendar revenues.

Using a valuation based on enterprise value to sales is easier for unprofitable companies. If Finjan were to generate $53 million in sales in 2017, we could see the market putting a 3.4 times sales multiple on it as shown in the industry average below. Using that and working back to enterprise value per share, we see that given those revenues, Finjan could be worth $8.33 per share by 2017, assuming it still has the same amount of cash on the balance sheet as today and achieves those revenue levels in 2016 by licensing in addition to whatever settlement is received from Blue Coat if the appeal is won.

	Ticker	Revenue		EV/	EBIDTA	Enterprise Value / Sales		Included	Enterprise
Company		2015E	LTM	EBITDA	Margin	2015E	LTM	in Average?	Value
Interdigital	IDCC	$407	$416	6.7x	55%	3.7x	3.6x	y	$1,510
Inventergy Globa	INVT	$4	$5	-4.4x	-110%	5.1x	3.8x	y	$19
Neonode	NEON	$13	$8	-9.5x	-125%	7.1x	11.9x	y	$94
Parkervision	PRKR	$0	$0	-0.7x	NM	135.5x	NM	n	$15
Pendrell	PCO	$29	$44	-28.9x	13%	0.7x	0.5x	y	$21
Rambus	RMBS	$293	$292	11.1x	34%	3.8x	3.8x	y	$1,100
RPX	RPXC	$287	$287	2.0x	72.90%	1.4x	1.4x	y	$407
Tessera	TSRA	$273	$271	6.7x	73%	4.9x	4.9x	y	$1,330
Unwired Planet	UPIP	$5	$5	-1.2x	-780%	9.1x	9.4x	n	$42
VirnetX	VHC	$20	$2	-4.6x	NM	8.5x	112.6x	n	$170
Vringo	VRNG	NA	$1	-1.1x	NM	NM	38.4x	n	$20
Wi-Lan	WILN	$101	$99	1.0x	72%	0.7x	0.7x	y	$72
Average				**-1.9x**	**11%**	**3.4x**	**3.8x**		**$569**

	Revenue		EBITDA	Enterprise Value / Sales		Valuation Range	
	2017E	LTM	Margin	2017E	LTM	Low	High
Finjan	**$53**	**$1**	**-243.00%**	**3.4x**	**3.8x**	**$3**	**$181**

Conclusion of Enterprise Value	**$181,311,999**
Market Value	**$188,511,999**
Shares Outstanding	22,640,611
Price per Share	**$8.33**

Another way to look at possible revenues from current activity is to compare the relevant revenues of the various companies involved. We are taking a general guess that 20% of Websense's revenues were affected by Finjan patents which resulted in a licensing fee of $8 million at this stage in the litigation. This was settled before the Markman Hearing. Blue Coat went through the full trial and was awarded $40

million. If this is appealed and the company wins on appeal, the sum will be higher as interest and royalties for additional products sold during the litigation process is added on. Looking at the rest of the companies we can derive revenues over $224 million for similar licensing at the same stage as Websense. Judgments, of course, may be all over the place.

	Revenues	% Relevant		License	Judgment
FireEye	$428	30%	$128	$13	
Blue Coat	500	10%	$50	27	$40
Websense	400	20%	$80	8	
Proofpoint	186	50%	$93	9	
Sophos	420	25%	$105	11	
Symantec	4,200	30%	$1,260	126	
Palo Alto Networks	710	42%	$300	30	
TOTAL				**224**	

Cybersecurity companies

The new consulting venture will have different peer comparables where valuations are much higher. For example, FireEye bought Madiant for $1 billion or approximately 7 times sales. Another comparable would be root9b, a company with $141 million enterprise value and a run rate of $38 million, or 3.7 times.

RISKS

- The company has a limited track record with which to set expectations.
- There is no way to predict the timing of lawsuit settlements or licensing agreements, or even the length of a lawsuit.
- As the current company burns cash and has little licensing revenue, it may not generate enough revenues to cover costs and continue operations in the future unless it generates greater income or receives further financing.
- The stock is high risk and is expected to have wide swings in stock price depending on unpredictable events.
- Government is expected to legislate new laws on patent enforcement that could affect the company's ability to monetize its patents as it currently expects.

INCOME STATEMENT

\

	2014				2015				2016							
In Thousands	**Q1R**	**Q2R**	**Q3R**	**Q4**	**Q1**	**Q2**	**Q3**	**Q4E**	**Q1E**	**Q2E**	**Q3E**	**Q4E**	**2013R**	**2014**	**2015E**	**2016E**
Websense	$0	$0	$4,998	$0	$0	$0	$0	$0	$2,000	$0	$0	$0	$0	$4,998	$0	$2,000
Other licenses					0	700	0	0	2,250	2,250	2,250	2,250	0	0	700	9,000
Consulting & Products					0	0	0	300	300	400	550	750	0	0	300	2,000
Blue Coat									0	0	0	0	0	0	0	0
Total Revenues	**0**	**0**	**4,998**	**0**	**0**	**700**	**0**	**300**	**4,550**	**2,650**	**2,800**	**3,000**	**0**	**4,998**	**1,000**	**13,000**
Cost of revenues	0	0	800	0	0	60	0	20	255	186	196	210	0	800	80	1,900
Gross profit	0	0	4,198	0	0	640	0	280	4,295	2,465	2,604	2,790	0	4,198	920	11,100
Gross Margin			84%			91%		93%	94%	93%	93%	93%		84%	92%	85%
Operating Expenses:																
SG&A	1,792	3,332	3,535	5,157	4,205	4,413	4,490	4,000	4,500	4,600	4,600	4,600	6,225	13,813	17,108	18,300
R&D						146	206	250	250	260	265	280	0	0	602	1,055
Transaction costs	0	0	0	0	0	0	0	0	0	0	0	0	790	0	0	0
Total operating expenses	1,792	3,332	3,535	5,157	4,205	4,559	4,696	4,250	4,500	4,860	4,865	4,880	7,015	13,813	17,710	19,355
							1,596									
Operating Income	(1,792)	(3,331)	663	(5,157)	(4,205)	(3,919)	(4,696)	(3,970)	(205)	(2,396)	(2,261)	(2,090)	(7,015)	(9,615)	(16,790)	(8,255)
Other Income																
Gain on settlements	1,000	0	0	0	0	0	0	0	0	0	0	0	1,000	1,000	0	0
Other income	0	5	0	(5)	(1)	1,271	0	0	0	0	0	0	9	0	0	0
Interest income	68	6	8	8	9	7	(4)	0	0	0	0	0	153	90	12	0
Total other income		11	8	3	8	1,278	(4)	0	0	0	0	0	1,162	1,090	12	0
Loss before taxes	(724)	(3,320)	671	(5,154)	(4,196)	(2,634)	(4,700)	(3,970)	(205)	(2,396)	(2,261)	(2,090)	(5,853)	(8,525)	(16,778)	(8,255)
Income taxes	1	(2)	(2)	8	5	0	0	(5)	-	-	-	-	(260)	5	0	0
Tax rate									0%	0%	0%	0%				0%
Net Income	(725)	(3,322)	673	(5,146)	(4,201)	(2,634)	(4,700)	(3,965)	(205)	(2,396)	(2,261)	(2,090)	(5,593)	(8,520)	(16,778)	(8,255)
Net Income Per Share:																
Basic EPS from Cont.	**($0.03)**	**($0.15)**	**$0.03**	**($0.23)**	**($0.19)**	**($0.12)**	**($0.21)**	**($0.18)**	**($0.01)**	**($0.11)**	**($0.10)**	**($0.09)**	**($0.26)**	**($0.38)**	**($0.74)**	**($0.37)**
Diluted EPS	($0.03)	($0.15)	$0.03	($0.21)	($0.19)	($0.12)	($0.19)	($0.18)	($0.01)	($0.11)	($0.09)	($0.09)	($0.26)	($0.38)	($0.69)	**($0.34)**
Basic Shares	22,368	22,379	22,422	22,445	22,409	22,519	22,562	22,641	22,641	22,519	22,562	22,641	21,602	22,404	22,533	22,591
Diluted Shares	23,993	23,876	22,541	24,250	24,315	24,435	24,468	24,547	24,547	24,425	24,468	24,547	23,227	24,209	24,441	24,497
Stock-based Comp	338	618	971	-479	355	355	642	642	642	642	642	642	1189	1448	1994	2568
Non-GAAP Income	(387)	(2,704)	1,644	(5,625)	(3,846)	(2,279)	(4,058)	(3,323)	437	(1,754)	(1,619)	(1,448)	(4,404)	(7,072)	(14,784)	(5,687)
Non-GAAP EPS	**($0.02)**	**($0.12)**	**$0.07**	**($0.25)**	**($0.17)**	**($0.10)**	**($0.18)**	**($0.15)**	**$0.02**	**($0.08)**	**($0.07)**	**($0.06)**	**($0.20)**	**($0.32)**	**($0.66)**	**($0.25)**

BALANCE SHEET


$ in Thousands	Sept 30, 2015	June 30, 2015	% Change
Current assets:			
Cash and cash equivalents	$7,156	$11,905	-40%
Accounts receivable, net	-	-	
Prepaid expenses and other current assets	241	218	11%
Total current assets	7,397	12,123	-39%
Property and equipment, net	295	250	18%
Investments	1945	1445	35%
Other long term assets	301	231	30%
Total Assets	9,938	14,049	-29%
Current Liabilities:			
Accounts payable	2,148	1,479	45%
Accounts payable - related parties	8	8	0%
Accrued expenses	437	798	-45%
Accrued income taxes	8	8	0%
Total current liabilities	2,601	2,293	13%
Other non-current liabilities	65	0	
Total Liabilities	2,666	2,293	16%
Stockholders' Equity			
Common stock	2	2	0%
Additional paid-in capital	23,817	23,601	1%
Retained earnings	(16,547)	(11,847)	40%
Total Stockholders' Equity	7,272	11,756	-38%
Total Liabilities & Stockholders' Equity	$9,938	$14,049	-29%
Cash per fully diluted share	$0.29	$0.49	-40%

CASH FLOW

CASH FLOWS (Unaudited) - $ in Thousands

	Sept. 30, 2015	Jun. 30, 2015	March 31, 2015
Cash flows from operating activities:			
Net loss	$ (4,700)	$ (2,641)	$ (4,202)
Adjustments to reconcile net loss to net cash used in operating activities:			
Loss on discontinued operations	$ 0	$ 0	$ 0
Gain on Investment	$ 0	$ (1,271)	$ 0
Depreciation and amortization	$ 9	$ 19	$ 7
Stock-based compensation	$ 187	$ 100	$ 355
Deferred tax liability	$ 0	$ 0	$ 0
Changes in operating assets and liabilities:			
Accounts receivable	$ 0	$ 55	$ 1,961
Inventories	$ 0	$ 0	$ 0
Prepaid expenses and other current assets	$ (23)	$ (153)	$ 47
Other long-term assets	$ (70)	$ (231)	$ 0
Accrued expenses	$ (361)	$ (44)	$ 42
Accounts payable	$ 669	$ 152	$ (348)
Accounts payable - related parties	$ 0	$ (10)	$ (82)
Other long term assets	$ 65	$ 231	$ (231)
Other current liabilities	$ 0	$ 0	$ 0
Accrued income taxes	$ 0	$ 0	$ 8
Total Adjustments	$ 0	$ (1,397)	$ 1,397
Net cash used in operating activities	$ (4,224)	$ (3,793)	$ (2,443)
Cash flows from investing activities:			
Purchases of property and equipment	$ (54)	$ (133)	$ (77)
Proceeds from investment	$ 0	$ 826	$ 0
Purchase of additional investment	$ (500)	$ 0	$ 0
Net cash provided by (used in) investing activities	$ (554)	$ 693	$ (77)
Proceeds from exercise of stock options			
Proceeds from exercise of stock options	$ 29	$ 0	$ 20
Net cash provided by financing activities	$ 29	$ 0	$ 20
Net decrease in cash and cash equivalents	$ (4,749)	$ (3,100)	$ (2,500)
Cash and cash equivalents - beginning	$ 11,905	$ 15,005	$ 17,505
Cash and cash equivalents - ending	$ 7,156	$11,905	$ 15,005
Non-cash investing and financing activities			
Additional investment held by investee	$ 0	$ 445	$ 0
Purchase of property and equipment in exchange for finance agreement	$ 0	$ 0	$ 0
Cash Flow	$ (4,504)	$ (3,793)	$ (3,840)

STOCK PRICE CHART



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Lisa Thompson, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESMENT BANKING, REFERRALS, AND FEES FOR SERVICE

Zacks SCR does not provide nor has received compensation for investment banking services on the securities covered in this report. Zacks SCR does not expect to receive compensation for investment banking services on the Small-Cap Universe. Zacks SCR may seek to provide referrals for a fee to investment banks. Zacks & Co., a separate legal entity from ZIR, is, among others, one of these investment banks. Referrals may include securities and issuers noted in this report. Zacks & Co. may have paid referral fees to Zacks SCR related to some of the securities and issuers noted in this report. From time to time, Zacks SCR pays investment banks, including Zacks & Co., a referral fee for research coverage.

Zacks SCR has received compensation for non-investment banking services on the Small-Cap Universe, and expects to receive additional compensation for non-investment banking services on the Small-Cap Universe, paid by issuers of securities covered by Zacks SCR Analysts. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, equity research, investment management, non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per client basis and are subject to the number of services contracted. Fees typically range between ten thousand and fifty thousand USD per annum.

POLICY DISCLOSURES

Zacks SCR Analysts are restricted from holding or trading securities placed on the ZIR, SCR, or Zacks & Co. restricted list, which may include issuers in the Small-Cap Universe. ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Each Zacks SCR Analyst has full discretion on the rating and price target based on his or her own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for services described above. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but are not guaranteed as to be accurate nor do we purport to be complete. Because of individual objectives, this report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

ZACKS RATING & RECOMMENDATION

ZIR uses the following rating system for the 1129 companies whose securities it covers, including securities covered by Zacks SCR:
Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters.
Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters.
Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution is as follows: Buy/Outperform- 15.4%, Hold/Neutral- 74.9%, Sell/Underperform – 8.9%. Data is as of midnight on the business day immediately prior to this publication.